Industry update tracker: July 2026
A monthly index of company press releases and announcements shaping the real-world data (RWD), real-world evidence (RWE) and health technology assessment (HTA) landscape.
Across Healthcare Matrix Partners with C-Path to Expand Rare Disease Data Platform Through Direct Integration
Critical Path Institute (C-Path), a nonprofit that builds data and analytics tools to speed drug development, announced a partnership with Across Healthcare’s Matrix platform to expand its Rare Disease Cures Accelerator–Data and Analytics Platform (RDCA-DAP). Under a new master data-sharing agreement, de-identified patient data from Matrix will flow into RDCA-DAP through a direct digital integration, a continuous pipeline rather than a periodic, manual upload. The result is a faster, more current stream of RWD for researchers studying rare diseases and developing treatments for them.
Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
Dexcom, the global leader in glucose biosensing, announced it is the first company selected by the US FDA to participate in the Technology-Enabled Meaningful Patient Outcomes (TEMPO) Pilot Program, a first-of-its-kind initiative designed to evaluate innovative digital health technologies that improve chronic disease management while generating RWE.
Flatiron Health Expands Global Oncology Network Through First Partnership In Scotland
Flatiron Health, a global healthcare technology company dedicated to improving cancer care and advancing research using RWD, announced a new partnership between Flatiron Health UK and NHS Greater Glasgow and Clyde (NHSGGC), the largest health board in Scotland. The collaboration marks Flatiron's first partnership in Scotland and further expands its growing international oncology network across the UK, Germany, and Japan.
Jiro Launches a New Practice Intelligence Platform Built Entirely Around the Clinician
Jiro Health announced the launch of its Practice Intelligence platform, introducing a new category of software designed to help clinicians benefit from the RWD they generate every day.
John Snow Labs and 3Aware Announce Partnership to Deliver Multimodal De-Identification Inside the 3Aware Evidence Vault
John Snow Labs announced a formal partnership with 3Aware to integrate their world-class multimodal de-identification capabilities directly into the 3Aware Evidence Vault. This collaboration enables health systems to unlock governed, privacy-protected real-world clinical data for research and commercial applications at scale – while keeping sensitive data and analytics securely within the provider’s environment.
Longevity AI and Researchers from Meir Medical Center of the Clalit Health Group Collaborate on Chronic Disease Risk Prediction Research
Longevity AI, a clinical intelligence company helping healthcare organizations deliver proactive, preventive care at scale, announced a joint research collaboration with clinicians and researchers from Meir Medical Center of the Clalit Health Services Group. The research focuses on evaluating and refining clinical risk prediction models for cardiovascular disease and type 2 diabetes, using longitudinal RWD from Clalit’s integrated healthcare system.
As GLP-1 Indications Expand, Novellia Launches Patient Registry to Fill Knowledge Gaps Left by Traditional Datasets
Novellia, the RWD company that unifies patients' clinical histories across every provider and payer they've used, announced the launch of its GLP-1 and Metabolic Health Registry, designed to give healthcare organizations unparalleled visibility into how these therapies are actively performing in diverse, real-world populations.
Nucs AI and Segmed Partner to Build the Data Foundation for Precision Oncology
Nucs AI, a company developing AI-powered diagnostic and predictive imaging biomarkers for oncology and theranostics, and Segmed, a leader in real-world clinical and imaging data, announced a strategic partnership to build the validation foundation for the next generation of AI in oncology. By bringing together Segmed’s diverse, multi-institutional data library with Nucs AI’s predictive models, this partnership attacks the data bottleneck that has constrained the field.
OneMedNet Secures $11.5+ Million Agreement to Supply Regulatory-Grade Real-World Data for Foundational AI Model Development
OneMedNet Corporation, a leading provider of regulatory decision-grade, AI-driven RWD, announced it has entered into an agreement to supply its regulatory-grade, multi-modal imaging-centric iRWD™ platform data for use in the development and training of a foundational AI model. Under the terms of the agreement, OneMedNet will provide high-quality, de-identified, regulatory-grade healthcare data, including millions of medical imaging and associated clinical reports, with data delivery immediately.
Thermo Fisher Scientific Launches PPD CorEvitas Vitiligo Registry to Advance Real-World Evidence in Nonsegmental Vitiligo
Thermo Fisher Scientific, the world leader in serving science, announced the launch of the PPD™ CorEvitas™ Vitiligo Registry, a prospective, observational clinical registry designed to generate longitudinal RWE in adolescents and adults living with nonsegmental vitiligo (NSV). The CorEvitas Vitiligo Registry is designed to address these gaps through the prospective collection of longitudinal RWD from patients with NSV across the US. The registry will evaluate the long-term effectiveness of approved treatments while generating insights into disease burden, natural history, treatment utilization, patient outcomes and unmet needs.
| Register for free today to become a member of The Evidence Base and receive the latest news straight to your inbox. |